Published in Am J Gastroenterol on June 01, 2012
Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.44
Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol (2013) 0.93
Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92
Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology (2016) 0.91
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs (2015) 0.91
The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon (2013) 0.90
The influence of dietary fat on liver fat accumulation. Nutrients (2014) 0.90
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care (2015) 0.88
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci (2016) 0.87
Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol (2014) 0.87
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2014) 0.84
p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci (2013) 0.84
Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat (2012) 0.83
Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One (2016) 0.82
From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. Am J Physiol Endocrinol Metab (2014) 0.81
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. Genes Nutr (2014) 0.81
Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci (2016) 0.81
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
Development of non-alcoholic fatty liver disease scoring system among adult medical check-up patients: a large cross-sectional and prospective validation study. Diabetes Metab Syndr Obes (2015) 0.80
Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. Int J Clin Exp Med (2014) 0.78
Histological Assessment of NAFLD. Dig Dis Sci (2016) 0.78
In vivo and ex vivo measurements: noninvasive assessment of alcoholic fatty liver using 1H-MR spectroscopy. Diagn Interv Radiol (2015) 0.78
Probiotics and liver disease. Perm J (2013) 0.78
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) (2016) 0.77
Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther (2015) 0.77
Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult BMI: The CARDIA study. Obesity (Silver Spring) (2014) 0.77
A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging. P R Health Sci J (2015) 0.77
Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram. Cureus (2017) 0.76
Evaluation of fatty liver fibrosis in rabbits using real-time shear wave elastography. Exp Ther Med (2014) 0.76
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol (2016) 0.76
Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep (2016) 0.76
The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Integr Med Insights (2016) 0.75
Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J (2016) 0.75
Characterisation of liver fat in the UK Biobank cohort. PLoS One (2017) 0.75
Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Sci Rep (2016) 0.75
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol (2016) 0.75
Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease. World J Hepatol (2016) 0.75
Assessment of Diet and Physical Activity in Paediatric Non-Alcoholic Fatty Liver Disease Patients: A United Kingdom Case Control Study. Nutrients (2015) 0.75
Caution in Using Non-Invasive Scoring Systems in NAFLD Beyond Highly Selected Study Populations. Am J Gastroenterol (2017) 0.75
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther (2016) 0.75
High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss. Sci Rep (2017) 0.75
Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol (2016) 0.75
The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol (2017) 0.75
Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice. PLoS One (2017) 0.75
Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Dig Dis Sci (2016) 0.75
Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis. Dig Dis Sci (2016) 0.75
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury. FEBS J (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A (2003) 17.10
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol (2009) 12.16
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 10.84
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
Liver biopsy. Hepatology (2009) 7.61
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol (2013) 5.96
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Diagnosis and management of autoimmune hepatitis. Hepatology (2010) 5.27
ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol (2013) 5.09
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol (2013) 4.36
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Nonalcoholic fatty liver disease. Gastroenterology (2002) 4.15
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (2014) 4.01
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol (2005) 3.86
Clinical guideline: management of gastroparesis. Am J Gastroenterol (2012) 3.86
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
AGA technical review on the clinical use of esophageal manometry. Gastroenterology (2005) 3.67
American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology (2007) 3.66
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA (2003) 3.51
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology (2005) 3.35
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
AASLD guidelines for treatment of chronic hepatitis B. Hepatology (2015) 3.32
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2002) 2.98
American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology (2004) 2.98
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 2.93
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology (2010) 2.83
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.79
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr (2003) 2.77
Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation (2008) 2.70
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 2.63
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56